Results 61 to 70 of about 1,265,475 (213)

Differential expression of brain cannabinoid receptors between repeatedly stressed males and females may play a role in age and gender-related difference in traumatic brain injury: Implications from animal studies

Frontiers in Neurology, 2014
Inconsistent gender differences in the outcome of TBI have been reported. The mechanism is unknown. In a recent male animal study, repeated stress followed by TBI had synergistic effects on brain gene expression and caused greater behavioral deficits ...
Guoqiang eXing, Guoqiang eXing, Janis eCarlton, Xiaolong eJiang, Jillian eWen, Jillian eWen, Min eJia, He eLi   +7 more
doaj   +1 more source

Cannabigerol reverses mechanical allodynia through α2A‐adrenergic modulation of thalamocortical signaling in chemotherapy‐induced neuropathy

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and treatment‐resistant side effect of platinum‐based chemotherapy, characterised by mechanical allodynia. Cannabigerol (CBG), a non‐psychoactive cannabinoid, has shown antinociceptive potential, but its site and mechanism of action remain unclear.
Quinn W. Wade, Nathan Morris, Diana E. Sepulveda, Alonso Cortez‐Resendiz, Christopher Brandl, Jennifer E. Lausch, Mariya Starostina, Nicholas M. Graziane   +7 more
wiley   +1 more source

Interaction of Synthetic Cannabinoid Receptor Agonists with Cannabinoid Receptor I: Insights into Activation Molecular Mechanism [PDF]

, 2020
The manuscript of a paper entitled "Interaction of Synthetic Cannabinoid Receptor Agonists with Cannabinoid Receptor I: Insights into Activation Molecular Mechanism".
Anton, Bashilov, Sergei, Gavryushov, Nikolay, Kuzmich, Boris, Izotov, Konstantin, Cherashev-Tumanov, Tatyana, Burykina   +5 more
core   +2 more sources

Signal detection and characterisation of a novel drug–drug interaction between methadone and a synthetic cannabinoid receptor agonist

British Journal of Pharmacology, EarlyView.
Background and Purpose Little is known about how synthetic cannabinoid receptor agonist (SCRA) co‐use with other psychoactive substances may exacerbate risk of death. This study aimed to characterise the polypharmacy of deaths where SCRAs were detected at post‐mortem, investigate the cardiotoxicity of SCRAs and probe their inhibition of human ether‐a ...
Kirsten L. Rock, Louise M. Hesketh, Hongwei Cheng, Shuoqi Chen, Simon Hudson, Graeme Henderson, Jules C. Hancox, Michael J. Shattock, Michael J. Curtis, Caroline S. Copeland   +9 more
wiley   +1 more source

Peripheral cannabinoid receptor, CB2, regulates bone mass.

, 2006
The endogenous cannabinoids bind to and activate two G protein-coupled receptors, the predominantly central cannabinoid receptor type 1 (CB1) and peripheral cannabinoid receptor type 2 (CB2).
Attar-Namdar, Malka, Wright, Karen, Ofek, Orr, Karsak, Meliha, Shohami, Esther, Zimmer, Andreas, Kram, Vardit, Leclerc, Nathalie, Tam, Joseph, Fogel, Meirav, Frenkel, Baruch, Mechoulam, Raphael, Bab, Itai   +12 more
core   +4 more sources

CB1 and CB2 Receptor Expression in Type 1 Diabetic Neuropathic Rats Is Enhanced by Photobiomodulation Therapy

Photonics
Background: The interaction between the endocannabinoid system (ECS), specifically the CB1 and CB2 cannabinoid receptors, and neuropathy has aroused great research interest due to the possible implications for treatment.
Danielle Paula Freitas Bataus Silva, Natalia Vendrame, Willians Fernando Vieira, Marucia Chacur   +3 more
doaj   +1 more source

Cannabinoid CB2 receptor ligands disrupt the sequential regulation of p-MEK1/2 to p-ERK1/2 in mouse brain cortex

Exploration of Neuroprotective Therapy, 2023
Aim: The sequential phosphorylation of mitogen-activated protein (MAP) kinases MEK-ERK is the most relevant cellular signaling pathway. This study quantified the parallel in vivo regulation of brain phosphorylation-MEK1/2 (p-MEK1/2) to p-ERK1/2 by ...
Glòria Salort, María Álvaro-Bartolomé, Jesús A. García-Sevilla   +2 more
doaj   +1 more source

The Cannabinoid CB2 Receptor as a Target for Inflammation-Dependent Neurodegeneration [PDF]

Current Neuropharmacology, 2007
Endocannabinoids are released following brain injury and may protect against excitotoxic damage during the acute stage of injury. Brain injury also activates microglia in a secondary inflammatory phase of more widespread damage. Most drugs targeting the acute stage are not effective if administered more than 6 hours after injury.
John C, Ashton, Michelle, Glass
openaire   +2 more sources

The ongoing oleoylethanolamide story: Therapeutic implications in the control of obesity and its comorbidities

British Journal of Pharmacology, EarlyView.
The global burden of obesity continues to rise, demanding effective pharmacological strategies for individuals in whom prevention alone is insufficient. Recent incretin‐based and multi‐agonist therapies have delivered unprecedented weight loss, demonstrating that the simultaneous modulation of multiple metabolic pathways can optimize body weight ...
Marzia Friuli, Alessia Campagna, Barbara Eramo, Christian Sepe, Annarita Zuena, Silvana Gaetani, Adele Romano   +6 more
wiley   +1 more source

Binding thermodynamics at the human cannabinoid CB1 and CB2 receptors [PDF]

Biochemical Pharmacology, 2010
The thermodynamic parameters DeltaG degrees , DeltaH degrees and DeltaS degrees of the binding equilibrium of agonists and antagonists at cannabinoid CB(1) and CB(2) receptors were determined by means of affinity measurements at different temperatures and van't Hoff plots were constructed.
MERIGHI, Stefania, SIMIONI, Carolina, GESSI, Stefania, VARANI, Katia, BOREA, Pier Andrea   +4 more
openaire   +2 more sources